Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification
In this real-world cohort, mavacamten treatment was associated with sustained symptomatic and echocardiographic improvements, suggesting a favorable disease-modifying impact with minimal need for septal reduction therapy.
Authors
- Zoran Popović (ORCID: https://orcid.org/0000-0001-5692-2299)
- Andrew Gaballa (ORCID: https://orcid.org/0009-0008-8619-3400)
- Milind Y. Desai (ORCID: https://orcid.org/0000-0003-0010-9797)
- Craig R. Asher
- Katy Rutkowski
- Susan Ospina (ORCID: https://orcid.org/0009-0004-7175-6582)
- Sanaa Sultana
- Bo Xu (ORCID: https://orcid.org/0000-0002-2985-7468)
- Maran Thamilarasan
- Yuichiro Okushi (ORCID: https://orcid.org/0009-0004-8534-6760)
- Shada Jadam (ORCID: https://orcid.org/0009-0005-6175-4775)
- Mohammed Abusafia (ORCID: https://orcid.org/0009-0008-8658-8656)
Institutions
- Cleveland Clinic (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1161/jaha.125.044537
- Citations
- 2
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.78